Form 6-K Trident Digital Tech For: Jun 17
Tweet
Share
E-mail UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 6-K
_________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Commission File Number: 001-41848
_________________
Trident Digital Tech Holdings Ltd
(Exact name of registrant as specified in its charter)
_________________
Suntec Tower 3,
8 Temasek Boulevard Road, #24-03
Singapore, 038988
(Address of principal executive office)
_________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Trident Digital Tech Holdings Ltd |
||||||
|
By: |
/s/ Soon Huat Lim |
|||||
|
Name: |
Soon Huat Lim |
|||||
|
Title: |
Chairman and Chief Executive Officer |
|||||
Date: June 17, 2026
1
EXHIBIT INDEX
|
Exhibit No. |
Description |
|
|
Exhibit 99.1 |
||
|
Exhibit 99.2 |
||
|
Exhibit 99.3 |
Third Amended and Restated Memorandum and Articles of Association |
2
ATTACHMENTS / EXHIBITS
PROXY CARD FOR THE EXTRAORDINARY GENERAL MEETING
THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trident Digital Tech Holdings (Nasdaq: TDTH) Activates National RDC-PASS Digital Identity Ecosystem in the Democratic Republic of Congo Under 20-Year Public-Private Partnership
- Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
- CARBIOS presents the results of its Annual General Meeting of June 18, 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
